Cogent Biosciences Inc. (NASDAQ: COGT) is one of the best emerging technology stocks to invest in. On December 19, JPMorgan ...

Cannabis Bioscience International Holdings, Inc. engages in the provision of educational systems that focuses on medical cannabis in the United States and Latin America, and internationally. The ...

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity ...

Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial FlexibilityBroadOak Partner ...

MBX Biosciences Inc. (NASDAQ:MBX) is one of the stocks that will double in 2026. On December 4, Goldman Sachs initiated coverage of MBX Biosciences with a Sell rating and $18 price target.

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced ...

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101 ...

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE” or the “Company”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company has appointed Jeff ...

Xenetic stockholders as of the close of business on the October 15, 2025 record date for the Annual Meeting, or their legal proxy holders, will be able to attend the reconvened Annual Meeting by ...

Shares of Jade Biosciences, Inc. (JBIO) have gained 25% over the past four weeks to close the last trading session at $12, but there could still be a solid upside left in the stock if short-term price ...

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.55 per share a year ago. These ...

"I would like to thank all those that have voted for the December 3, 2025, Special Meeting and remind all those who have not yet voted to vote," said James Rolke, Chief Executive Officer, Revelation.